An expanded role for MRI and 2 recently approved treatment options.
Mark L. Fuerst
Menopause, obesity, and bacterial infection all have a negative impact on RA, according to 3 recent studies.
An online tool for juvenile arthritis, guidelines on childhood lupus, and good news about the response to treatment for ANCA-associated vasculitis
Up to 30% of psoriasis patients will develop psoriatic arthritis. Studies show that a proportion of patients in clinical care have undiagnosed PsA.
Experts now believe that psoriatic arthritis should be considered a risk factor for cardiovascular diseases, including stroke.
In this slideshow, we highlight five of the top concerns and questions physicians have about switching patients from one biologic to another in psoriatic arthritis.
Tumor necrosis factor inhibitors have transformed the treatment of psoriatic arthritis. However, switching TNF inhibitors two or three times is not uncommon.
Epidemiological evidence points to an intimate relationship between intestinal inflammation and joint inflammation, such as psoriatic arthritis.
Apremilast may represent a new oral treatment option for patients with psoriatic arthritis (PsA) and current skin involvement, according to a new study.
A new study finds that slightly more than one-third of the patients were adherent to their index biologic and almost half discontinued within 12 months of initiation of therapy.